Rumalon immunogenicity in patients with osteoarthritis
Study involving people · 2000
- What was studied
- 31 patients with osteoarthritis, in exposure-history groups of 17, 6, 4 and 4.
- Main finding
- The 31-patient immunogenicity study reported Rumalon-specific IgG4 and type-2 cytokine responses after exposure.
Serum IL-5 · 407.4 ± 257.1 vs 1,409.4 ± 963.1 pg/mL · Before treatment in the 17-person group versus the two longest-exposure groups combined (8 people). · p<0.001
Reported findings and study design
Serum and cellular immune assays across groups with different numbers of prior injection series.
Population or model 31 patients with osteoarthritis, in exposure-history groups of 17, 6, 4 and 4.
Protocol information
Sera were sampled before and after one injection series in 17 patients. The remaining groups had 2–3, 4–8 or 9–18 previous series. Dose per injection is not reported in the abstract.
Protocol source ↗ · Original indexed abstract.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Serum IL-5 | 407.4 ± 257.1 vs 1,409.4 ± 963.1 pg/mL | Before treatment in the 17-person group versus the two longest-exposure groups combined (8 people). · p<0.001 |
| Serum IL-10 | 950.2 ± 867.8 vs 2,817.8 ± 3,127.3 pg/mL | Same exposure-group comparison. · p<0.05 |
| Rumalon-specific IgG4 and type-1 cytokines | IgG4 responses reported. Type-1 cytokines were unchanged. |
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- The endpoint was immunogenicity. These laboratory markers do not establish a clinical benefit or harm.
Source details
Original indexed abstract.
Sources checked
Citation
R. Klein, E. W. Becker, P. A. Berg, A. Bernau. Rumalon immunogenicity in patients with osteoarthritis Journal of Rheumatology. 2000;27(2):448–454. PMID 10685813.